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Giant cell tumor of bone (GCTB) accounts for 5% of primary skeletal tumors. Although it is considered to be a
benign lesion, there are still incidences of pulmonary metastasis. Pulmonary metastasis of GCTB may be affected by
tumor grading and localization as well as the age, gender and overall health status of the patient. Patients with
local recurrence are more likely to develop pulmonary metastasis of GCTB. High expression of some genes,
cytokines and chemokines may also be closely related to the metastatic potential and prognosis of GCTB. The
treatment of the primary GCTB is key to the final outcome of the disease, as intralesional curettage has a
significantly higher local recurrence and pulmonary metastasis rate than wide resection. However, even patients
with pulmonary metastasis seem to have a good prognosis after timely and appropriate surgical resection. It is
hoped that with the development of novel surgical methods and drugs, pulmonary metastasis of GCTB can be
prevented and treated more effectively.
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Giant cell tumor of bone (GCTB) is a primary intrame-
dullary tumor which is supposedly benign but can be
locally aggressive and even metastatic [1-3]. Its name
originated from the giant cells found within the tumor.
Those giant cells share specific markers with osteoclasts
such as tartrate-resistant acid phosphatase [4], cathepsin
K [5], carbonic anhydrase II [6], calcitonin receptor [7]
and receptor activator of nuclear factor-κB (RANK) [8].
They both have bone resorption capabilities, but giant
cells are significantly larger than the osteoclasts and have
hundreds of nuclei [9].
GCTB account for 5% of primary skeletal tumors
and 21% of all benign bone tumors [10,11]. It has the
highest prevalence among the population aged be-
tween 20 and 40-years-old and has a slight female pre-
dominance [12], with the female to male ratio of 1.3 to
1.5:1.0 [13]. The most usual sites for GCT include
distal femur, proximal tibia and distal radius [14-18].
The incidence of GCTs in small bones is less than 1%
of all GCT cases [19,20].* Correspondence: niuxiaohui@263.net
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article, unless otherwise stated.Diagnosis of giant cell tumor of bone
Conventional diagnostic methods of GCTB include its
clinical, radiological and histopathological manifesta-
tions. Diagnostically, typical clinical manifestations of
GCTB include regional pain, swelling and occasionally
history of pathological fracture [21]. Radiographs demon-
strate an eccentric lytic lesion with cortical extension.
Histologically, GCT consists of multiple multinucle-
ated giant cells with strong phenotypic similarities to
osteoclasts and spindle-shaped proliferative stromal
cells [15,22].
More recently, the increasingly popular application of
novel imaging techniques such as positron emission tom-
ography/computerized tomography (PET/CT) has made
the diagnosis of primary and metastatic GCTB more ac-
curate [23]. Furthermore, basic research has also provided
diagnostic gene markers such as P53, P63 and P73 [24,25],
as well as KTN 1, NEB, ROCK1 and ZAK [26]. However,
more research is needed before these biomarkers can be
used in clinical practice.Pulmonary metastasis of giant cell tumor of bone
Prevalence
Although rare, GCTB can be multicentric or arise in lo-
cations where it is difficult to be surgically removed. TheCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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from local bony destruction to local metastasis. The
distant metastasis and malignant transformation are
extremely rare conditions [27]. Rare cases of metasta-
ses to other sites have been described in the literature.
Those reported include the lung, lymph nodes [28],
liver, soft tissue [29], brain, mediastinum, scalp, kidney
and penis.
Based on the current literature, approximately 3% of
GCTB metastasizes to the lung (Table 1). Pulmonary
metastasis is very rarely discovered during diagnosis of
the initial GCTB, but more frequently in cases of recur-
rence. The interval from the time of surgery on the pri-
mary lesion to the occurrence of pulmonary metastasis
can be as little as several months or more than 10 years.
However, in most cases metastases were found within
three years after the surgical treatment of the initial
lesion [30,31]. Based on the current literature (Table 1),
approximately 3% of GCTB metastasizes to lung at cer-
tain time points after the confirmed diagnosis of primary
GCTB.
Factors related to the pulmonary metastasis of giant cell
tumor of bone
There is no consensus on which factors may affect the
likelihood of pulmonary metastasis of GCTB. However,Table 1 Some studies on pulmonary metastasis of giant cell
tumors of bone





Errani et al. 2010 [32] 91 (36-204) months 349 4%
Kremen et al. 2012 [33] 0.1-312 months 230 2%
Takeuchi et al. 2011 [34] 2-180 months 110 7.5%
Klenke et al. 2011 [35] 108 (36-233)months 118 4.2%
Viswanathan et al. 2010 [36] 4 months-12 years 470 1.7
Balke et al. 2008 [37] 60 (8-280) months 214 3.3%
Donthineni et al. 2006 [38] 18-126months 51 13.7%
Faisham et al. 2006 [39] 12-60 months 20 30%
Dominkus et al. 2006 [30] 3 months to
11.9 years
649 2.1%
Prosser et al. 2005 [40] 70 (24-214) months 137 1.6%
Su et al. 2004 [41] 62 (28-138) months 87 1.2%
Trieb et al. 2001 [42] 11 (4-43) years 47 0%
Blackley et al. 1999 [43] 80 (29-132) months 59 1.7%
O’Donnell et al. 1994 [44] 4 (2-10) years 60 0%
Kay et al. 1994 [45] 23-120 months 66 9.1%
Campanacci 1 et al. 987 [1] 2-44 years 280 2.1%
McDonald et al. 1986 [46] 84 (min 24) months 146 3.2%several independent studies on some special types of
GCTB may bring some insights into this issue. For
example, Faisham et al. [39] have reported a pulmon-
ary metastasis ratio of 30% in patients with grade 3
GCTB by Campanacci’s classification, indicating that
the tumor grading might be an important prognostic
factor for the prediction of pulmonary metastasis
of GCTB. Donthineni et al. [38] have reported a
pulmonary metastasis ratio of 13.7% in patients with
GCTB which occur primarily on spine, and Errani
et al. [32] reported a higher incidence of pulmonary
metastasis of GCTB located in proximal femur and
distal radius, indicating that the location of primary
lesion might also be a prognostic factor. However,
most authors believe that there is no significant rela-
tionship between the location of GCTB and its risk of
pulmonary metastasis.
Rock et al. [47] had reported a six-fold higher risk of
lung metastasis in patients who experienced local
recurrence of GCTB compared with patients with no
history of local recurrence. Studies by Rock and several
other authors indicate that higher risk patients with
recurrent GCTB should be carefully monitored for
pulmonary metastases after the appropriate treatment
of the recurrent lesion (Table 2). Most studies assume
that local recurrence of GCTB is a risk factor for lung
metastasis.
Moreover, literature of basic research has also pro-
vided us with methods to predict the possibility of pul-
monary metastasis. For example, pro-osteoclastogenicTable 2 Studies involving the relationship between local
recurrence and pulmonary metastasis of GCTB







Kremen et al. 2012 [33] 230 5 28
Klenke et al. 2011 [35] 118 5 24
Errani et al. 2010 [32] 349 14 52
Prosser et al. 2005 [40] 137 22 26
Trieb et al. 2001 [42] 47 0 11
Blackley et al. 1999 [43] 59 10 12






470 8 13 of 24 patients with
lung metastasis




218 6 5 of 6 patients with
lung metastasis
Table 3 Recurrence rates after different surgical treatment of giant cell tumors of bone








Klenke et al. 2011 [35] 118 5 N/A 32 + phenol + burrin:15
Errani et al. 2010 [32] 349 12 N/A 18
Balke et al. 2008 [37] 214 0 140 47 +phenol: 38
Kivioja et al. 2008 [11] 294 12 51 N/A 22
Knochentumoren 2008 [52] 256 2 49 N/A +phenol:69
Malek et al. 2006 [56] 40 N/A N/A 33 N/A
McGough et al. 2005 [57] 183 N/A 46 N/A N/A
Prosser et al. 2005 [40] 137 0 N/A N/A +burring: 21
Su et al. 2004 [41] 87 3 N/A N/A +phenol: 18
Turcotte et al. 2002 [55] 186 34 N/A N/A +phenol + burring:55
Blackley et al. 1999 [43] 59 N/A N/A 12 N/A
Campanacci et al. 1987 [1] 280 0 27 N/A 8
McDonald 1986 [45] 146 7 N/A 34 N/A
Results from the current literature implies that the recurrence ratio of GCT is: Intralesional curettage > Intralesional curettage + regional burring > Intralesional
curettage + local adjuvants + PMMA > Wide resection.
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kappa-B ligand (RANKL), interleukin (IL)-6 and tumor
necrosis factor (TNF), as well as monocyte-recruiting
chemokines such as stromal cell-derived factor-1 (SDF-1)
and monocyte chemoattractant protein (MCP)-1, par-
ticipate in unfavorable osteoclastogenesis and bone
destruction [49]. High expression of those cytokines
and chemokines may help predicting the metastatic
potential and prognosis of GCTB.Table 4 Number of patients with the incidence of pulmonary
metastasis of giant cell tumors of bone








Kremen et al. 2012 [33] 230 5 4
Takeuchi et al. 2011 [34] 110 8 8
Errani et al. 2010 [32] 349 14 10*Treatment
Treatment of giant cell tumor of bone is still one of
the most controversial and discussed issues [50]. The
course of progression of metastatic pulmonary disease
has been found to be as unpredictable as the primary
tumor [51]. Since the incidence of pulmonary metas-
tasis of GCTB is rather rare, there is no study on the
systematic treatment of metastatic GCTB in the
current literature. However, since the recurrence rate
of GCTB is significantly related to its pulmonary me-
tastasis, studies concerning treatment methods and
the recurrence rate of GCTB may provide guidance
for the prevention of metastasis and achieve a better
prognosis.Klenke et al. 2011 [35] 118 5 4
Viswanathan et al. 2010 [36] 470 8 8
Faisham et al. 2006 [39] 20 6 5
Dominkus et al. 2006 [30] 649 14 14
Donthineni et al. 2006 [38] 51 7 5
Kay et al. 1994 [45] 7 7 6
*3 of the 4 patients died of causes irrelevant to GCTB.Surgical treatment
Surgical treatment options for primary GCTB lesions in-
clude intralesional surgery and wide resection. Intrale-
sional surgery has a higher recurrence rate but does
preserve adjacent joint function. On the other hand,
although wide resection may prevent metastasis, itmay seriously impair the function of adjacent joints.
When curettage is performed, local adjuvants such as
polymethylmethacrylate (PMMA), phenol, alcohol, cryo-
therapy and hydrogen peroxide have been reported to
significantly decrease the rate of local recurrence and
pulmonary metastasis [10,11,38,52,53]. However, some
other studies [40,54] failed to find any positive thera-
peutic effect of these adjacent measures. In a Scandi-
navian Sarcoma Group multicentric study by Kivioja
et al. [11] involving 294 patients, the recurrence rate
of GCTB was 20% in patients treated with bone
cement, which is significantly lower (P = 0.001) than
the 56% recurrence rate in patients who underwent
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trary, in a Canadian multicentric study of 186 patients
by Turcotte et al. [55], filling the remnant cavity with
bone cement did not significantly reduce the recur-
rence rate of GCTB (Table 3).
Moreover, Enneking’s and Campanacci’s classifica-
tions [2,58] are helpful tools for planning the initial
surgical treatment. For instance, stage III GCTB is
best managed with wide resection for better local
control. Faisham et al. [39] proposed that aggressiveFigure 1 A 22-year-old female patient came to the orthopedic clinic c
bone scan tests found a sub-articular lucent lesion with clear boundatreatment of pulmonary metastasis is mandatory in
the management of aggressive GCTB. Surgical exci-
sion of solitary and surgically-accessible lesions as
well as lung metastases is now widely accepted as the
treatment of choice, with an acceptable long-term
survival rate [45].
Drug treatment
The anti-osteoclastic effects of bisphosphonates, along
with their ability to protect bone from further resorption,omplaining of continuous pain of left knee, X-ray,CT, MRI and
ries on the left distal femoral bone.
Figure 3 18 months after the first surgery, CT and bone scan found
Figure 2 Pathological examination was fine needle biopsy
confirmed it was giant cell tumor. Local curettage and bone
grafting was performed by the local hospital.
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ment of GCTB, and studies have confirmed their efficacy
[59]. Balke et al. [37] examined clinical and radiological
outcomes of treatment with amino bisphosphonates
on 25 cases of aggressive primary, recurrent and
metastatic GCTB derived from four European cen-
ters. Most inoperable sacral or pelvic tumors did not
increase in size and no further recurrence or metasta-
sis was observed in patients with recurrent GCTB.
Lung metastases did not increase in size or number
following treatment, suggesting that bisphosphonates
may be useful against the progression of metastatic
GCTB lesion in lung.
Denosumab, a fully human monoclonal antibody that
specifically inhibits normal and tumor-associated bone
lysis by preventing RANKL-mediated formation and
activation of multinucleated osteoclasts or giant cells
from RANK-positive mono-nuclear preosteoclasts andlocal recurrence was found at follow-up visit.
Figure 4 She was treated with en bloc resection under the aid of computer navigation under intraoperative CT scan, and the cavity
was filled with bone cement. Intraoperative pathological exam confirmed the recurrence of GCTB.
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reduce the number of RANK-positive giant cells and
proliferative stromal cells [15]. In the study of Thomas
et al. [60], 30 out of 35 (86%; 95% CI 70 to 95) ofevaluable patients had a positive tumor response after
the treatment of denosumab. It is likely a novel and
effective method with great potential in the treatment
of GCTB [61].
Figure 5 34 months after the first surgery, multiple nodules were found by CT scan in both of her lungs on a follow-up visit.
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For lung metastasis, appropriate surgical resection such as
metastasectomy, wedge resection or lobectomy should be
carried out if it is possible to prevent progressive pulmon-
ary dysfunction [30,62]. Because pulmonary metastases are
rare and timely surgical and chemotherapeutic treatment is
usually successful (Table 4, see Figures 1, 2, 3, 4, 5 and 6
for an example case), we believe the potential for metasta-
ses should not by itself be an indication for wide resection
of primary tumors.Conclusions
In conclusion, GCTB is normally considered a benign
bone tumor. However, it may occasionally metastasize to
vital organs such as the lung. The prognosis can be suc-
cessful with timely and appropriate surgical treatment
and chemotherapy. With the development of novel
surgical methods and application of new drugs, most pa-
tients with GCTB can still achieve successful treatment
results.Figure 6 At the last follow-up visit 40 months after the first
surgery, Ct scan showed that the patient was alive with the
disease, complaining of no trouble with breathing.Abbreviations
CT: computerized tomography; GCTB: Giant cell tumor of bone;
IL: interleukin; MRI: magnetic resonance imaging; MCP: monocyte
chemoattractant protein; PMMA: polymethylmethacrylate; PET/
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